<DOC>
	<DOCNO>NCT00932529</DOCNO>
	<brief_summary>Despite different pharmacological property , scientific evidence inconclusive regard first-line second generation antipsychotic ( SGAs ) prefer individual patient suffer psychosis . The limitation evidence base may relate highly select sample , short duration , rigid experimental design randomize clinical trial efficacy . Moreover high proportion clinical trial drug company sponsor could introduce fund bias . The purpose non-commercially funded study investigate whether effectiveness difference exist among first-line SGAs olanzapine , quetiapine , risperidone , ziprasidone drug use representative clinical setting . Eligible patient admit hospital acute psychosis candidate oral antipsychotic treatment . The investigator hypothesise naturalistic set every-day clinical practice diverse sample representative patient admit symptom acute psychosis , differential effectiveness among SGAs could disclose patient follow 2 year . This could deliver valuable information regard SGA start antipsychotic drug order facilitate beneficial outcome .</brief_summary>
	<brief_title>Use , Effects Side-effects Second-generation Antipsychotics Naturalistic Setting</brief_title>
	<detailed_description />
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Psychosis Must able use oral antipsychotic drug Mania Unable cooperate assessment Unable understand Norwegian language Candidates electroconvulsive therapy Use Clozapine admittance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>Antipsychotic drug</keyword>
	<keyword>Treatment effectiveness</keyword>
	<keyword>Randomized control trial</keyword>
</DOC>